
|Videos|January 8, 2021
C. Difficile Treatment: Bezlotoxumab
The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.
Advertisement
Episodes in this series

Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Zoliflodacin Emerges as a First-in-Class Oral Option Against Drug-Resistant Gonorrhea
2
Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Meets Primary Endpoint in Phase 3 Study
3
FDA Approves Zoliflodacin for Uncomplicated Urogenital Gonorrhea
4
Top Infectious Disease News Stories Week of December 6 - December 12
5





































































































































































































































































































